Kalcipotriol
Klassificering: BATC kod: D05AX02, D05AX52
Sammanfattning
Inga studier med relevanta analyser av könsskillnader för farmakokinetik eller säkerhet har hittats men en liten studie med analys av könsskillnader av effekten av topikalt kalcipotriol visade inga skillnader i tid till remission.
Additional information
Pharmacokinetics and dosing
No difference between men and women has been shown for transdermal absorption in general [1].
Effects
In a study of patients with psoriasis vulgaris (43 men, 17 women) who had undergone narrowband ultraviolet B therapy and topical vitamin D3 (calcitriol/calcipotriene or maxacalcitol) the remission period from end of treatment to re-exacerbation was found to be similar in men and women [2].
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of calcitriol/calcipotriene have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Other information
In a study of children with psoriasis (74 boys, 51 girls) (60 were treated with calcitriol/calcipotriene, unknown distribution of boys and girls) showed that the boys were more severely affected than the girls [3].
A US survey study from 1994 to 2001 in (2,109,075 men, 3,721,931 women) showed a peak in calcitriol/calcipotriene use in women during the first three years after its introduction 1994 and a large use off label, but after four years from introduction the use became quite similar in men and women [4].
A database including patients (469 men, 568 women) from outpatient clinics specialized in chronic pruritus showed sex and gender differences in etiology, presentation and impact and quality of life of the disease [5].
Försäljning på recept
Något fler män än kvinnor hämtade ut läkemedel innehållande kalcipotriol (ATC-kod D05AX02) på recept i Sverige år 2016, totalt 127 män och 117 kvinnor. Det motsvarar 0,03 respektive 0,02 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 75-79 år hos män och 60-64 år hos kvinnor. I genomsnitt var läkemedel innehållande kalcipotriol 1,5 gånger vanligare hos män [6].
Uppdaterat: 2017-06-19
Litteratursökningsdatum: 2017-05-10
Referenser
- Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
- Karakawa M, Komine M, Takekoshi T, Sakurai N, Minatani Y, Tada Y et al. Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris. J Dermatol. 2011;38:655-60. PubMed
- Stefanaki C, Lagogianni E, Kontochristopoulos G, Verra P, Barkas G, Katsambas A et al. Psoriasis in children: a retrospective analysis. J Eur Acad Dermatol Venereol. 2011;25:417-21. PubMed
- Pearce DJ, Camacho F, Balkrishnan R, Fleischer AB, Feldman SR. Trends in on and off-label calcipotriene use. J Dermatolog Treat. 2006;17:308-13. PubMed
- Ständer S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168:1273-80. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.] länk
Faktagranskat av: Mia von Euler
Godkänt av: Karin Schenck-Gustafsson